Pharma News
Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.
CStone, Pfizer Enter into Strategic Collaboration to Address Oncological Needs in China
Wednesday, September 30, 2020CStone Pharmaceuticals and Pfizer Investment Co Ltd Pfizer Investment and Pfizer Corporation Hong Kong Limited announced the formation of a strategic collaboration that encompasses a million equity investment by Pfizer Hong Kong in CStone collaborat...
FibroGenesis Announces Manufacturing Agreement with iBiologics
Tuesday, September 29, 2020FibroGenesis the leading developer of fibroblast based therapeutic solutions for unmet medical needs is pleased to announce it has entered into a manufacturing agreement with iBiologics to supply its proprietary allogeneic fibroblast cells to support...
Vor Biopharma and Arbor Biotechnologies to Collaborate on Engineered Hematopoietic Stem-Cell Therapies
Tuesday, September 29, 2020Vor Biopharma an oncology company pioneering engineered hematopoietic stem cells eHSCs for the treatment of cancer and Arbor Biotechnologies an earlystage life sciences company today announced an agreement to use Arbors gene editing technologies to e...
AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease
Monday, September 28, 2020AVROBIO Inc a leading clinicalstage gene therapy company with a mission to free people from a lifetime of genetic disease announced that the European Commission EC has granted orphan drug designation for AVRRD the companys investigational gene therap...
Vivet Therapeutics and Pfizer Inc. Sign Agreement to Manufacture Investigational Gene Therapy Product Developed by Vivet for Wilson's Disease
Saturday, September 26, 2020Vivet Therapeutics Vivet a privately held gene therapy biotechnology company dedicated to developing treatments for severe inherited liver diseases and Pfizer Inc announced that have signed a manufacturing agreement under which Pfizer will supply th...
AbCellera and IGM Biosciences Announce Multi-Year Antibody Discovery Collaboration
Friday, September 25, 2020AbCellera and IGM Biosciences Inc announced today that they have entered into a multiyear multitarget strategic research collaboration and license agreement to facilitate the discovery and development of novel IgM antibodies
Lumen Bioscience Awarded Federal Grant to Rapidly Develop Nanobody-based Covid-19 Therapeutic
Friday, September 25, 2020Lumen Bioscience a clinicalstage biopharmaceutical company developing biologic drugs for highly prevalent diseases and the US Army Medical Research and Development Command USAMRDC operating through the Medical Technology Enterprise Consortium MTEC an...
Samsung Biologics signs strategic partnership with Kanaph Therapeutics to develop treatment for retinal diseases
Thursday, September 24, 2020Samsung Biologics and Kanaph Therapeutics have entered into a strategic partnership to develop KNP a bispecific Fc fusion protein intended to treat retinal diseases According to Kanaph Therapeutics KNP is designed to target autoimmune diseases by inh...
InSysBio announces its collaboration with Genmab
Thursday, September 24, 2020InSysBio one of the worlds pioneers of Quantitative Systems Pharmacology QSP modeling announces its collaboration with Genmab an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics...
Anokion Announces Expansion of Exclusive Collaboration with Bristol Myers Squibb to Develop Novel Treatments for Autoimmune Diseases
Wednesday, September 23, 2020Anokion SA a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance announced the expansion of an exclusive global collaboration agreement with Bristol Myers Squibb focused on developing therapeutics f...
